drugset / Trial / NCT01732770

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

NCT01732770

Phase 4 Completed 643 enrolled Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.

Timeline

Start
2012-11-07
Primary completion
2015-01-07
Completion
2015-01-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 60 mg Subcutaneous
Comparator Zoledronic acid Other / unclassified 5 mg Intravenous